Return to search

Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl

Aim: To investigate the relationship between effective fentanyl sublingual spray (FSS) doses for breakthrough cancer pain (BTCP) and around-the-clock (ATC) transdermal fentanyl patch (TFP). Methods: Adults tolerating ATC opioids received open-label FSS for 26 days, followed by a 26-day double-blind phase for patients achieving an effective dose (100-1600 mu g). Results: Out of 50 patients on ATC TFP at baseline, 32 (64%) achieved an effective dose. FSS effective dose moderately correlated with mean TFP dose (r = 0.4; p = 0.03). Patient satisfaction increased during the study. Common adverse events included nausea (9%) and peripheral edema (9%). Conclusion: FSS can be safely titrated to an effective dose for BTCP in patients receiving ATC TFP as chronic cancer pain medication. ClinicalTrials.gov identifier: NCT00538850

Identiferoai:union.ndltd.org:arizona.edu/oai:arizona.openrepository.com:10150/621765
Date10 1900
CreatorsAlberts, David S, Smith, Christina Cognata, Parikh, Neha, Rauck, Richard L
ContributorsUniversity of Arizona
PublisherFUTURE MEDICINE LTD
Source SetsUniversity of Arizona
LanguageEnglish
Detected LanguageEnglish
TypeArticle
RightsThis work is licensed under the Creative Commons Attribution-NonCommercial 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-nd/4.0/
Relationhttp://www.futuremedicine.com/doi/10.2217/pmt-2015-0009

Page generated in 0.0021 seconds